These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15868945)

  • 21. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
    Skaland I; Øvestad I; Janssen EA; Klos J; Kjellevold KH; Helliesen T; Baak JP
    J Clin Pathol; 2008 Jan; 61(1):68-71. PubMed ID: 17412872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
    Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
    Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
    Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
    Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
    van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
    BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
    Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
    Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
    Chuang TC; Liu JY; Lin CT; Tang YT; Yeh MH; Chang SC; Li JW; Kao MC
    FEBS Lett; 2007 Sep; 581(23):4443-9. PubMed ID: 17719580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
    Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
    Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of primary breast carcinomas grown in three-dimensional cultures.
    Becker JL; Blanchard DK
    J Surg Res; 2007 Oct; 142(2):256-62. PubMed ID: 17727885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas.
    Uzawa N; Sonoda I; Myo K; Takahashi K; Miyamoto R; Amagasa T
    Cancer; 2007 Nov; 110(10):2230-9. PubMed ID: 17893905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
    Li H; Weinstein IB
    Cancer Res; 2006 Dec; 66(23):11399-408. PubMed ID: 17145886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.